FREE Account Opening + No Clearing Fees

Global Longlife BSE SME IPO review (Avoid)

Review By Dilip Davda on April 18, 2022

•    GLHRL is a multi-speciality health care services provider. 
•    Last three fiscal's financial data show inconsistency.
•    Super earnings for FY22 9M raises eyebrows and doubt over window dressing.
•    Despite super earnings, the IPO pricing is very high.
•    There is no harm in ignoring this pricy bet

The company filed its draft prospectus for an IPO of Rs. 49 cr. with NSE for listing on SME Emerge on November 20, 2021, but failing to get clearance till February 2022, it filed a draft prospectus with BSE on March 02, 2022, and got approval soon thereafter to submit its final prospectus with ROC on April 11, 2022. This is a major concern as it shifted to BSE SME from NSE SME listing raising eyebrows about the documents approval process. According to primary market sources, NSE has somewhat stringent criteria for approval of draft documents compared to BSE for SME listings. Should this have bearing on an IPO process is a million-dollar question. 

Global Longlife Hospital and Research Ltd. (GLHRL) is known as a Multi-Speciality Tertiary Care Hospital in Gujarat with 110 beds well equipped for Medical & Surgical Specialities. As a policy, any doctor having experience of more than 3 years can admit his patient to the hospital. It provides a platform for doctors to treat their patients. As of 31st December 2021 apart from the 11 full-time consultants, it has a team of more than 30 experienced doctors as a consultant to serve patients. Its staff strength also comprises 37 nursing staff and more than 50 paramedical, corporate and support staff and pharmacists as on December 31, 2021.

The Company has adopted the Standard Operating Procedures (SOPs) given by the Ministry of Health & Family Welfare. Under the said SOPs every work function of the hospital is defined, every process is written down and every employee is trained in his/her duties as soon as he/she joins. All equipment is maintained as per a predefined schedule. Every necessary license is obtained and renewed as required from time to time.

GLHRL is certified by National Accreditation Board for Hospitals and Healthcare Providers ("NABH Accredited") which is committed to supporting the improvement of the quality of healthcare service in the country for all strata of the population through various methodologies and tools to supplement the efforts of the providers of healthcare service and the requirements of the system at various levels. Through the Mukhya Mantri Amrutum Yojana it has served over 6,000 patients up till now.

To part finance its needs for land acquiring on a leasehold (Rs. 20.00 cr.), repayment of loans (Rs. 14.80cr.) and general corporate purpose (Rs. 10.70 cr.), GLHRL is coming out with a maiden IPO of 3500000 equity shares of Rs. 10 each at a fixed price of Rs. 140 per share to mobilize Rs. 49.00 cr. The issue opens for subscription on April 21, 2022, and will close on April 25, 2022. Minimum application is to be made for 1000 shares and in multiples thereon, thereafter. Post allotment, shares will be listed on BSE SME. The issue constitutes 38.29% of the post issue paid-up capital of the company. GLHRL is spending Rs. 3.50 cr. for this IPO process. 

The IPO is solely lead managed by Interactive Financial Services Ltd. and Bigshare Services Pvt. Ltd. is the registrar to the issue. NNM Securities Pvt. Ltd. is the market maker for this company. 

Having issued most of the equity shares at par, the company has also issued some equity portions at a price of Rs. 15 per share in October 2012. The average cost of acquisition of shares by the promoters is Rs. 2.92 and Rs. 20.69 per share. 

Post-IPO, GLHRL's current paid-up equity capital of Rs. 7.00 cr. will stand enhanced to Rs. 10.50 cr. Based on the IPO pricing, the company is looking for a market cap of Rs. 

On the financial performance front, for the last three fiscals, GLHRL has posted total revenue/net profits of Rs. 34.70 cr. / Rs. 1.36 cr. (FY19), Rs. 33.66 cr. / Rs. - (0.86) cr. (FY20) and Rs. 32.77 cr. / Rs. 1.04 cr. (FY21). For the first nine months of FY22 ended on December 31, 2021, it has earned a net profit of Rs. 3.86 cr. on a revenue of Rs. 26.74 cr. After an inconsistent performance for the previous three fiscals, a quantum jump in the bottom line for the current fiscal partial operation raises eyebrows. This leads to doubt for some window dressing in its financial performance in the IPO year to get better valuations and lure investors. 

For the last three fiscals, GLHRL has reported an average EPS of Rs. 0.75 and an average RoNW of 4.84%. The issue is priced at a P/BV of 7.41 based on its NAV of Rs. 18.89 as of December 31, 2021, and at a P/BV of 2.54 based on its post-IPO NAV of Rs. 55.21 per share. 

If we annualize FY22 earnings and attribute it to the fully diluted post IPO equity capital then the asking price is at a P/E of 38.04 and if we take FY21 earnings, then the asking price is at a P/E of 140. Thus the IPO is priced exorbitantly. 

The company has not declared any dividends for the reported period of the offer documents. It will adopt a prudent dividend policy post listing based on its financial performance and future prospects. 

As per offer documents, GLHRL has shown Aashka Hospitals and KMC Speciality Hospitals as its listed peers. They are currently trading at a P/E of 27.64 and 42.43 (as of April 18, 2022). However, they are not truly comparable on an apple-to-apple basis. 

This is the 2nd mandate from Interactive Financial in the last two fiscals (including the ongoing one). The only listing that took place opened at a discount of 50% on a listing day. Thus it has a very poor track record so far. 

Conclusion / Investment Strategy

The company that originally filed its offer documents for NSE SME listing is now settling for BSE SME listing and raises concern over the IPO approval process. Boosted profits for the current fiscal first nine months’ performance raises eyebrows and suspension on window dressing for such fancy valuation and lure investors. Despite super earnings for 9M-FY22, its IPO pricing is at a higher P/E of 38. There is no harm in skipping this pricy bet.

Reviewer recommends Avoid to the issue.

Review By Dilip Davda on April 18, 2022

Review Author

DISCLAIMER: No financial information whatsoever published anywhere here should be construed as an offer to buy or sell securities, or as advice to do so in any way whatsoever. All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions. My reviews do not cover GMP market and operators game plans. Readers must consult a qualified financial advisor before making any actual investment decisions, based the on information published here. With entry barriers, SEBI wants only well-informed investors to participate in such offers. With crazy listings in the recent past, SME IPOs drew the attention of investors across the board and lead to seer madness. However, as SME issues have entry barriers and continued low preference from the broking community, any reader taking decisions based on any information published here does so entirely at their own risk. The above information is based on information available as of date coupled with market perceptions. The Author has no plans to invest in this offer.

About Dilip Davda

Dilip Davda

Dilip Davda is veteran journalist associated with stock market since 1978. He is contributing to print and electronic media on stock markets/insurance/finance since 1985.

Dilip Davda is a leading reviewer of public issues and NCDs in the primary stock market in India. The knowledge he gained over 3 decades while working in the stock market and a strong relationship with popular lead managers makes his reviews unique. His detail fundamental and financial analysis of companies coming up with IPO helps investors in the primary stock market. Dilip Davda has a special interest in analyzing the SME companies and writing reviews about their public issues. His reviews are regularly published online and in news papers.

(Dilip Davda -SEBI registered Research Analyst-Mumbai,

Registration no. INH000003127 (Perpetual)

Email id: ).

Global Longlife Hospital IPO FAQs

  1. 1. Why Global Longlife Hospital IPO?

    The initial public offer (IPO) of Global Longlife Hospital and Research Limited offers an early investment opportunity in Global Longlife Hospital and Research Limited. A stock market investor can buy Global Longlife Hospital IPO shares by applying in IPO before Global Longlife Hospital and Research Limited shares get listed at the stock exchanges. An investor could invest in Global Longlife Hospital IPO for short term listing gain or a long term.

  2. 2. How is Global Longlife Hospital IPO?

    Read the Global Longlife Hospital IPO recommendations by the leading analyst and leading stock brokers.

  3. 3. Global Longlife Hospital IPO what should investors do?

    Global Longlife Hospital IPO offers an opportunity to buy IPO shares before they get listed at the stock exchanges. Read the Global Longlife Hospital IPO Notes, Analysis and Recommendations by leading stock brokerage firms and experts in the above answer.

  4. 4. Is Global Longlife Hospital IPO good?

    Our recommendation for Global Longlife Hospital IPO is to avoid.

  5. 5. Is Global Longlife Hospital IPO worth Investing?

    As per the analysis by our lead analyst Mr. Dilip Davda, we suggest you to avoid the Global Longlife Hospital IPO.

  6. 6. When will Global Longlife Hospital IPO allotment status?

    The Global Longlife Hospital IPO allotment status will be available on or around [.]. The allotted shares will be credited in demat account by [.]. Visit Global Longlife Hospital IPO allotment status to check.

  7. 7. When will Global Longlife Hospital IPO list?

    The Global Longlife Hospital IPO will list on Wednesday, May 4, 2022, at BSE SME.